Change 5-day change 1-year change 3-year change Capi.($)
+2.37%+2.30%+3.39%+23.26% 48.63B
-0.67%+4.29%+485.82%+616.64% 46.3B
+2.45%+5.41%+21.11%+92.98% 41.97B
+3.86%+3.38%+29.90%+16.57% 39.51B
-0.72%-7.79%+17.87%+47.98% 31.75B
+2.69%+1.75%+31.44%+146.94% 16.48B
+4.88%+2.40% - - 16.34B
+1.44%+1.52%+4.22%+31.44% 14B
+3.78%+2.24%+83.45%+44.71% 13.33B
Average +2.24%-0.60%+84.65%+127.56% 29.81B
Weighted average by Cap. +1.90%-0.05%+107.09%+155.65%
Logo Wize Pharma Inc
Wize Pharma Inc, formerly Ophthalix, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions. The Company markets, sells and distributes a formula known as LO2A, which protects ocular surface tissues. LO2A is a drug developed for the treatment of DES and other ophthalmological illnesses, including conjunctivochalasis (CCH) and sjogren's syndrome (sjogren's).
Employees
-